メニュー
Request a Quote
お問い合わせ
JP
tpd-protac1920x640
Application Note

Transforming preclinical leukemia research with no-wash immunoassays for BRD4-targeted degradation

Targeted protein degradation (TPD) is reshaping leukemia research by offering a novel approach to breaking down BRD4, a key driver in Acute Lymphoblastic Leukemia (ALL). BRD4, a member of the BET protein family, plays a crucial role in gene regulation and disease progression, making it a significant therapeutic target. While traditional small- molecule inhibitors have been widely used, they often struggle with incomplete inhibition and the development of resistance. TPD offers a novel approach by leveraging the cell’s natural degradation pathways to selectively eliminate BRD4, providing a more effective and durable therapeutic strategy.

Key highlights include:

  • A case study on BRD4 degradation in leukemia models
  • Comparative analysis of treatment responses
  • Best practices for optimizing HTRF™ assays

Discover how HTRF based immunoassays empower preclinical leukemia research and accelerate drug discovery.

For research use only. Not for use in diagnostic procedures

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Transforming preclinical leukemia research with no-wash immunoassays for BRD4-targeted degradation

Download Application Note